The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

April 6, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson & Johnson’s drug Remicade (infliximab), to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine.

You Might Also Like
  • Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
  • FDA Approves Amgen’s Infliximab Biosimilar Treatment
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

Inflectra, also known as infliximab-dyyb, is expected by some analysts to sell for a 25% discount to Remicade, which generated annual worldwide sales of $6.5 billion. Of that, $4.5 billion were in the U.S. Merck & Co. sells Remicade in Europe. Celltrion sells the biosimilar overseas under the brand Remsima.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Remicade, as well as similar drugs made by AbbVie Inc. and Amgen Inc., work by blocking an inflammation-causing protein called tumor necrosis factor. Dozens of anti-TNF biosimilars are in development.

Inflectra, made by Celltrion Inc. and Pfizer Inc.’s Hospira unit, is the second biosimilar approved by the FDA. A year ago, the agency approved Novartis AG’s Zarxio, which is similar to Amgen Inc’s white blood cell-boosting drug, Neupogen (filgrastim).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Remicade and Neupogen are biologic drugs made from living organisms. Copies of biologic products cannot easily be replicated and are known as biosimilar, not generic, because they are similar, not identical, to the original.

“Biosimilars can provide access to important treatment options for patients who need them,” Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, said in a statement. “Patients and the health care community can be confident that biosimilar products are high quality and meet the agency’s rigorous scientific standards.”

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biosimilars, FDA, Food and Drug Administration, infliximab, infliximab-dyyb

You Might Also Like:
  • Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
  • FDA Approves Amgen’s Infliximab Biosimilar Treatment
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade
  • Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)